Literature DB >> 14317460

SIMULTANEOUS CORRECTION OF MULTIVALVULAR CARDIAC LESIONS.

P GRONDIN, G LEPAGE, Y CASTONGUAY.   

Abstract

Cardiac surgery, once confined to pure and isolated mitral stenosis, can now be carried out on all valvular lesions irrespective of their number or complexity. At the Montreal Heart Institute, simultaneous surgical correction of multivalvular lesions was carried out in 16 instances and 13 patients survived. All of the survivors have remained almost asymptomatic. However, if significant associated valvular lesions were not corrected at the same operation, the survival rate dropped to 28%. Moreover, such survivors have required constant medical therapy.This experience emphasizes the necessity of correcting completely and simultaneously all significant valvular malfunctions. Extrapleural median sternotomy appears to be the best single approach for all cases of valve replacement.

Entities:  

Keywords:  HEART DISEASES; HEART SURGERY; HEART VALVE PROSTHESIS; HEART VALVES; POSTOPERATIVE COMPLICATIONS

Mesh:

Year:  1965        PMID: 14317460      PMCID: PMC1928689     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  4 in total

1.  COMBINED REPLACEMENT OF THE AORTIC AND MITRAL VALVES WITH A CAGED BALL VALVE PROSTHESIS.

Authors:  A N GEREIN; R H GOURLAY; E J GRAY; H V RICE; F W MCCAFFREY; D KAVANAGH-GRAY
Journal:  Can Med Assoc J       Date:  1964-06-13       Impact factor: 8.262

2.  Combined aortic and mitral valve replacement.

Authors:  R S CARTWRIGHT; J W GIACOBINE; R S RATAN; W B FORD; W E PALICH
Journal:  J Thorac Cardiovasc Surg       Date:  1963-01       Impact factor: 5.209

3.  AORTIC AND MITRAL VALVE REPLACEMENT; EXPERIENCE WITH STARR-EDWARDS PROSTHESES.

Authors:  D B EFFLER; L K GROVES; R FAVALORO
Journal:  Arch Surg       Date:  1964-01

4.  A NEEDLE-VENT SAFEGUARD AGAINST SYSTEMIC AIR EMBOLUS IN OPEN-HEART SURGERY.

Authors:  L K GROVES; D B EFFLER
Journal:  J Thorac Cardiovasc Surg       Date:  1964-03       Impact factor: 5.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.